The researchers investigated whether enteral IgG could prevent neonatal necrotizing enterocolitis.
In the multi-center, double-blind trial, 768 infants were randomly assigned to receive human IgG 1200 mg/kg daily, and 761 to receive placebo, for up to 28 days.
Treatment began at the same time as enteral feeding.
The primary outcome measure was the proportion of infants who developed definite necrotizing enterocolitis during the trial. Any deaths that resulted from the disorder in the treatment and placebo groups were measured. Analysis was on an intention-to-treat basis.
The researchers found that 43 infants developed definite necrotizing enterocolitis in the IgG group, 10 of whom died.
In the placebo group, 41 infants contracted the disorder and 6 died.
|IgG supplementation did not reduce necrotizing enterocolitis|
25 infants on IgG and 36 on placebo had suspect necrotizing enterocolitis.
Dr Gregor Lawrence, of the PO Royal Brisbane Hospital, Brisbane, concluded on behalf of fellow authors, "Supplementation of enteral feeds with human IgG does not reduce necrotizing enterocolitis."